TARRYTOWN, N.Y., Feb. 13 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. , today announced that it will participate in the BIO CEO & Investor Conference, being held at The Waldorf Astoria Hotel in New York City. Michael M. Goldberg, M.D., Chairman and Chief Executive Officer, will present on Wednesday, February 15, 2006, at 10:00 a.m. EST.
The presentation will be broadcast live via the Internet. You may access the presentation by visiting the investor relations portion within the Emisphere Technologies web site: www.emisphere.com/ir.asp or directly at:
http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=EMIS&item_id=1190594
Please visit the site at least five minutes prior to start time for instructions. A replay will be available through April 28, 2006. Corresponding slides will also be posted to the Investor Relations portion of Emisphere's web site.
About Emisphere Technologies, Inc.
Emisphere Technologies, Inc. is a biopharmaceutical company pioneering the oral delivery of otherwise injectable drugs. Emisphere's business strategy is to develop oral forms of injectable drugs, either alone or with corporate partners, by applying its proprietary eligen(R) technology to those drugs or licensing its eligen(R) technology to partners who typically apply it directly to their marketed drugs. Emisphere's eligen(R) technology has enabled the oral delivery of proteins, peptides, macromolecules and charged organics. Emisphere and its partners have advanced oral formulations or prototypes of salmon calcitonin, heparin, insulin, parathyroid hormone, human growth hormone and cromolyn sodium into clinical trials. Emisphere has strategic alliances with world-leading pharmaceutical companies. For further information, please visit www.emisphere.com.
Emisphere Technologies, Inc.CONTACT: Elliot M. Maza, C.P.A, J.D., Chief Financial Officer, ofEmisphere Technologies, Inc., +1-914-785-4703
